Physiochemical drug properties associated with in vivo toxicological outcomes.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionCase Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryRational approaches to improving selectivity in drug designChemical libraries dedicated to protein-protein interactionsInnovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties.Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET BromodomainsRational methods for the selection of diverse screening compoundsDefining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributesAutomated design of ligands to polypharmacological profiles.SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity DataFundamentals of translational neuroscience in toxicologic pathology: optimizing the value of animal data for human risk assessment.Interpreting physicochemical experimental data sets.Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate.Predicting cytotoxicity from heterogeneous data sources with Bayesian learning.Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Challenges of antibacterial discoveryPhysicochemical drug properties associated with in vivo toxicological outcomes: a review.Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists.Probing the probes: fitness factors for small molecule tools.Amphiphile regulation of ion channel function by changes in the bilayer spring constant.Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: increasing hit rate via virtual screening methods.A leap into the chemical space of protein-protein interaction inhibitorsLead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasisFocused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space.Structure-based virtual screening for drug discovery: principles, applications and recent advances.pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.FAF-Drugs3: a web server for compound property calculation and chemical library design.Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Improving MM-GB/SA Scoring through the Application of the Variable Dielectric Model.Imbalance in chemical space: How to facilitate the identification of protein-protein interaction inhibitors.Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study.iPPI-DB: an online database of modulators of protein-protein interactions.Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs.GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.Predictive toxicology approaches for small molecule oncology drugs.Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Metabolites: have we MIST out the importance of structure and physicochemistry?Novel γ-secretase modulators: a review of patents from 2008 to 2010.
P2860
Q24273350-CD8685C1-32FD-4DFD-84CC-A335A3C86C29Q26749054-3CA96473-C167-4AFD-A33F-FEAE5F9A0139Q26865357-6B02F2E6-F162-4B14-A9A6-345116BE5D24Q27010681-0B830EC6-6D3C-433B-AA81-D6DEB091461FQ27308002-E9BA6FE8-71FD-4FF9-B7CA-74269412B140Q27680405-BE046780-9A67-4881-BC61-CAB6D9C18D94Q28303907-0720FCAA-526D-48C8-9A6C-4FB3679E3A96Q28728799-1DA96D3D-68E8-45EC-910F-B7C5E073782DQ30539786-AB1CAA25-5E05-4395-A906-77A43B1A65A1Q30585642-E9F9A2FE-C531-49B3-B262-2A248D80104BQ30869945-D89E55E9-E966-4CF4-92F6-41EF4973D7DBQ30967921-F1FB06FF-F4EC-49AA-BFC3-8D7D04D90555Q33598794-220E8010-83CF-4B8D-9C50-C5F7CAD58363Q33598799-AADDD160-A31E-442D-A5F6-B986E2EB5D2EQ33766983-ECDB4695-8899-4D9B-9F28-11A0859D51AAQ33784830-8D6986C0-3766-4D21-A638-46A0458992D9Q33793074-F210AA61-901A-4EC6-878B-12D27DE3A683Q33845886-3FC04DD3-2EBA-40F8-901D-A8EBD19ABC85Q33899493-D871049B-DEF3-4BF7-A660-DC3A1EC9186FQ34001269-2E90A5A5-3295-4144-BD18-0B60D3365C61Q34100444-F701F81C-CA41-45A7-B812-B4E1C9899204Q34180451-4BEC70E3-2AC0-4F08-A748-7AC6349046A7Q34287849-F8A1D057-024F-4DB7-A704-B103AFA1F693Q34725554-72A64A36-71DA-4CA4-A404-34093C2CD802Q35158672-F4F6A0A0-2A13-4F6A-AC04-292D405B07EAQ35282223-E4A89D35-2CEC-43CB-BFDF-507F8062163FQ35599192-EAF39B2B-9533-4DD0-933E-50C1B6115148Q35604907-7FA4A727-0758-49CF-9902-96A4268C52C5Q35814421-881B2411-9A9C-44AB-A0A7-2649A30C6980Q35955749-805B8D43-85D5-47D6-8C82-DE5D6F997636Q35976167-09D5A911-8915-49E1-BB98-48BD6BC95D25Q36091191-9BB39EF2-2BCD-4A9E-848C-BCAC5A85470EQ36435078-EA67686C-660D-4A85-880E-B2AED93D3DE2Q36517549-4A61B878-7827-4090-AEAC-7FEAC67F28A4Q37335823-C469B88D-124E-4E84-A247-D6A1B961F883Q37449692-D378A1FB-62B8-4F22-8C84-9CE70E90825EQ37675456-EA937360-6E14-44B6-8307-124C550B7166Q37740151-686438D4-E1DB-40F2-8FB2-DFA973B5699EQ37810225-1FAD7BCA-9290-41F8-8110-A4FCE01385BAQ37828163-E184C8DF-B59A-4509-BAD0-6237D4B4F1BF
P2860
Physiochemical drug properties associated with in vivo toxicological outcomes.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Physiochemical drug properties associated with in vivo toxicological outcomes.
@ast
Physiochemical drug properties associated with in vivo toxicological outcomes.
@en
Physiochemical drug properties associated with in vivo toxicological outcomes.
@nl
type
label
Physiochemical drug properties associated with in vivo toxicological outcomes.
@ast
Physiochemical drug properties associated with in vivo toxicological outcomes.
@en
Physiochemical drug properties associated with in vivo toxicological outcomes.
@nl
prefLabel
Physiochemical drug properties associated with in vivo toxicological outcomes.
@ast
Physiochemical drug properties associated with in vivo toxicological outcomes.
@en
Physiochemical drug properties associated with in vivo toxicological outcomes.
@nl
P2093
P1476
Physiochemical drug properties associated with in vivo toxicological outcomes.
@en
P2093
David A Price
Edmund Ellsworth
Enoch Huang
Gary A Decrescenzo
Jason D Hughes
Jens Loesel
Julian Blagg
Larry Whiteley
Michael E Gibbs
Nigel Greene
P304
P356
10.1016/J.BMCL.2008.07.071
P407
P577
2008-07-24T00:00:00Z